JP2000512652A - 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途 - Google Patents

腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途

Info

Publication number
JP2000512652A
JP2000512652A JP10502317A JP50231798A JP2000512652A JP 2000512652 A JP2000512652 A JP 2000512652A JP 10502317 A JP10502317 A JP 10502317A JP 50231798 A JP50231798 A JP 50231798A JP 2000512652 A JP2000512652 A JP 2000512652A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
hydroxy
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP10502317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000512652A5 (enExample
Inventor
エルフィ ビエデルマン
マックス ハスマン
ローランド ローセル
ベンノ ラッテル
フリードマン レイテル
バーバラ スチェイン
クラウス セイベル
クラウス ボークト
Original Assignee
クリンゲ ファーマ ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリンゲ ファーマ ジーエムビーエイチ filed Critical クリンゲ ファーマ ジーエムビーエイチ
Publication of JP2000512652A publication Critical patent/JP2000512652A/ja
Publication of JP2000512652A5 publication Critical patent/JP2000512652A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP10502317A 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途 Withdrawn JP2000512652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624668A DE19624668A1 (de) 1996-06-20 1996-06-20 Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
PCT/EP1997/003244 WO1997048397A1 (en) 1996-06-20 1997-06-20 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624668.7 1997-06-20

Publications (2)

Publication Number Publication Date
JP2000512652A true JP2000512652A (ja) 2000-09-26
JP2000512652A5 JP2000512652A5 (enExample) 2005-02-10

Family

ID=7797502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10502317A Withdrawn JP2000512652A (ja) 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途

Country Status (10)

Country Link
EP (1) EP0912176B1 (enExample)
JP (1) JP2000512652A (enExample)
AT (1) ATE224713T1 (enExample)
AU (1) AU3262497A (enExample)
DE (2) DE19624668A1 (enExample)
DK (1) DK0912176T3 (enExample)
ES (1) ES2181006T3 (enExample)
PT (1) PT912176E (enExample)
WO (1) WO1997048397A1 (enExample)
ZA (1) ZA975443B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528361A (ja) * 2002-03-27 2005-09-22 フジサワ ドイッチラント ゲーエムベーハー 脈管形成抑制剤としてのピリジルアミド
JP2010507643A (ja) * 2006-10-27 2010-03-11 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ ブラジキニン拮抗剤としての新規フェニルスルファモイルベンズアミド誘導体

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
JPH10338658A (ja) * 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
CA2340068A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
DE19908483A1 (de) * 1999-02-26 2000-10-05 Klinge Co Chem Pharm Fab Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
JP2004507465A (ja) * 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
AU2001290143A1 (en) 2000-09-29 2002-04-08 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0207445D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
PE20071159A1 (es) 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
WO2009156421A1 (en) 2008-06-24 2009-12-30 Topotarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
EP2342181A1 (en) 2008-08-29 2011-07-13 Topo Target A/S Novel urea and thiourea derivatives
EP2453883A1 (en) 2009-07-17 2012-05-23 Topo Target A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
CN106243023A (zh) 2010-09-03 2016-12-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物
CA2809391A1 (en) 2010-09-03 2012-03-08 Genentech, Inc. 4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
SG188367A1 (en) 2010-09-03 2013-04-30 Forma Tm Llc Novel compounds and compositions for the inhibition of nampt
CN103189356B (zh) * 2010-09-29 2015-11-25 英特维特国际股份有限公司 N-杂芳基化合物
JP6117104B2 (ja) 2010-11-15 2017-04-19 アッヴィ・インコーポレイテッド Ｎａｍｐｔおよびｒｏｃｋ阻害薬
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
AU2011367222B2 (en) 2011-05-04 2017-04-13 Forma Tm, Llc Novel compounds and compositions for the inhibition of NAMPT
BR112013028877A2 (pt) 2011-05-09 2017-01-31 Forma Tm Llc derivados de piperidina e composições para a inibição de nicotinamida fosforibosiltransferase (nampt)
CA2873097A1 (en) 2012-05-11 2013-11-14 Todd M. Hansen Pyridazine and pyridine derivatives as nampt inhibitors
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
HK1208450A1 (en) 2012-05-11 2016-03-04 Abbvie Inc. Nampt inhibitors
US9334264B2 (en) 2012-05-11 2016-05-10 Abbvie Inc. NAMPT inhibitors
HK1215579A1 (zh) 2012-11-29 2016-09-02 Karyopharm Therapeutics, Inc. 被取代的2，3-二氫苯並呋喃基化合物和其用途
KR102325247B1 (ko) 2013-07-03 2021-11-11 카리오팜 쎄라퓨틱스, 인코포레이티드 치환된 벤조퓨라닐 및 벤즈옥사졸릴 화합물 및 이의 용도
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
BR112019022445A2 (pt) 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
WO2019149637A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
KR20250107972A (ko) 2018-05-04 2025-07-14 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
BR112022008753A2 (pt) 2019-11-06 2022-07-19 Remedy Plan Inc Tratamentos de câncer direcionados a células-tronco cancerosas
US20240376074A1 (en) 2021-05-13 2024-11-14 Remedy Plan, Inc. Nampt inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
JPH05506027A (ja) * 1990-04-10 1993-09-02 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規ピリジンエステル
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528361A (ja) * 2002-03-27 2005-09-22 フジサワ ドイッチラント ゲーエムベーハー 脈管形成抑制剤としてのピリジルアミド
JP2010507643A (ja) * 2006-10-27 2010-03-11 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ ブラジキニン拮抗剤としての新規フェニルスルファモイルベンズアミド誘導体

Also Published As

Publication number Publication date
ATE224713T1 (de) 2002-10-15
DE19624668A1 (de) 1998-02-19
DK0912176T3 (da) 2003-01-13
ZA975443B (en) 1998-02-10
AU3262497A (en) 1998-01-07
WO1997048397A1 (en) 1997-12-24
DE69715861T2 (de) 2003-06-12
ES2181006T3 (es) 2003-02-16
EP0912176A1 (en) 1999-05-06
DE69715861D1 (de) 2002-10-31
PT912176E (pt) 2003-01-31
EP0912176B1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
JP2000512652A (ja) 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途
JP4225572B2 (ja) 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類
JP4855576B2 (ja) ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類
JP4570247B2 (ja) 新規なピペリジニル−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類
JP4225571B2 (ja) 細胞増殖抑制剤および免疫抑制剤としての新規なピリジルアルカン酸アミド類
US6903118B1 (en) Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
JP4838934B2 (ja) 細胞増殖抑制剤及び免疫抑制剤として有用なアリール−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類
KR100478405B1 (ko) 세포분열억제제및면역억제제로서의피리딜알켄-및피리딜알킨-산아미드
HK1021974B (en) Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040608

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20070322

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20080617

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080917